LLY logo

Eli Lilly and Company (LLY)

$1,415.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LLY

Market cap

$1.33T

EPS

30.81

P/E ratio

39.5

Price to sales

13.93

Dividend yield

0.489%

Beta

0.398637

Price on LLY

Previous close

$1,431.67

Today's open

$1,416.49

Day's range

$1,401.66 - $1,432.28

52 week range

$850.51 - $1,475.25

Profile about LLY

CEO

Dave Ricks

Employees

50000

Headquarters

Indianapolis, IN

Exchange

New York Stock Exchange

Shares outstanding

940745031

Issue type

Common Stock

LLY industries and sectors

Healthcare

Pharmaceuticals

News on LLY

Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says

The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats ​and rising uptake among men accelerate their use, researcher ‌Worldpanel by Numerator said on Thursday.

news source

Reuters • 2 hours ago

news preview

Worried investors are paying up for these stocks — some with up to 49% upside, analysts say

Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.

news source

Market Watch • 10 hours ago

news preview

Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients

Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.

news source

Barrons • Nov 17, 2026

news preview

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

Eli Lilly has achieved explosive revenue growth fueled by its expanding portfolio of next-generation metabolic and weight-loss drugs. Novo Nordisk maintains a deep global reach with established diabetes and obesity treatments currently available in more than 50 countries.

news source

The Motley Fool • Nov 17, 2026

news preview

Lilly to buy Calytrix Bio for up to $1.5 billion

Eli Lilly has agreed to acquire Calytrix Bio for ​up to $1.5 billion in cash to ‌expand the development of treatments for rare blood cancers, the privately held biotech said ​on Monday.

news source

Reuters • Nov 16, 2026

news preview

Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head

Retatrutide beat Ozempic in a head-to-head trial, highlighting Lilly's dominance in its core area. The GLP-1 market could reach $190 billion by 2035, and Eli Lilly leads the industry.

news source

The Motley Fool • Nov 16, 2026

news preview

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers.

news source

WSJ • Nov 16, 2026

news preview

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

news source

Zacks Investment Research • Nov 16, 2026

news preview

New research shows weight-loss drugs could be an effective option for children as young as 6 years old

Novo Nordisk's study of GLP-1s in children as young as 6 years old worked for shedding pounds but raised questions about growth rates.

news source

WSJ • Nov 16, 2026

news preview

Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027

Eli Lilly is surging, with revenue up 39% in the third quarter and a retatrutide filing planned for early 2027. Novo is bouncing back on oral Wegovy, with a CagriSema decision due soon.

news source

The Motley Fool • Nov 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Eli Lilly and Company

Open an M1 investment account to buy and sell Eli Lilly and Company commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LLY on M1